Axa Deferred Long Term Liab vs Cash And Equivalents Analysis

EQH Stock

USD 41.49 0.01 0.02%

Axa Equitable financial indicator trend analysis is way more than just evaluating Axa Equitable Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axa Equitable Holdings is a good investment. Please check the relationship between Axa Equitable Deferred Long Term Liab and its Cash And Equivalents accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Axa Equitable Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

Deferred Long Term Liab vs Cash And Equivalents

Deferred Long Term Liab vs Cash And Equivalents Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axa Equitable Holdings Deferred Long Term Liab account and Cash And Equivalents. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Axa Equitable's Deferred Long Term Liab and Cash And Equivalents is -0.42. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Cash And Equivalents in the same time period over historical financial statements of Axa Equitable Holdings, assuming nothing else is changed. The correlation between historical values of Axa Equitable's Deferred Long Term Liab and Cash And Equivalents is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Axa Equitable Holdings are associated (or correlated) with its Cash And Equivalents. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Equivalents has no effect on the direction of Deferred Long Term Liab i.e., Axa Equitable's Deferred Long Term Liab and Cash And Equivalents go up and down completely randomly.

Correlation Coefficient

-0.42

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Cash And Equivalents

Most indicators from Axa Equitable's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axa Equitable Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Axa Equitable Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

As of now, Axa Equitable's Selling General Administrative is increasing as compared to previous years. The Axa Equitable's current Enterprise Value Over EBITDA is estimated to increase to 4.36, while Tax Provision is forecasted to increase to (718.2 M).

	2021	2022	2023	2024 (projected)
Gross Profit	6.6B	10.4B	6.3B	7.5B
Total Revenue	11.0B	12.6B	10.5B	9.3B

Gross Profit Total Revenue

Axa Equitable fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab
Common Stock Shares Outstanding		-0.86	0.64	-0.86	0.24	0.66	-0.91	0.66	0.6	0.44	-0.83	-0.13	-0.75	-0.66	-0.5	0.29	-0.1	-0.73	0.42	0.08	0.58	-0.66	-0.87	-0.79	0.99	-0.91
Total Assets	-0.86		-0.76	0.62	-0.4	-0.22	0.97	-0.22	-0.48	-0.25	0.94	-0.1	0.6	0.37	0.65	-0.08	0.08	0.67	-0.57	0.23	-0.3	0.44	0.82	0.79	-0.85	0.99
Short Long Term Debt Total	0.64	-0.76		-0.66	0.59	0.12	-0.7	0.11	0.57	-0.12	-0.65	0.2	-0.57	-0.38	-0.47	0.11	-0.06	-0.25	0.6	-0.07	0.21	-0.45	-0.72	-0.71	0.63	-0.74
Other Current Liab	-0.86	0.62	-0.66		-0.22	-0.75	0.68	-0.75	-0.78	-0.28	0.59	0.26	0.92	0.89	0.4	-0.26	0.2	0.48	-0.58	-0.47	-0.51	0.88	0.77	0.67	-0.86	0.67
Total Current Liabilities	0.24	-0.4	0.59	-0.22		-0.15	-0.27	-0.15	-0.03	-0.09	-0.15	0.62	0.02	0.17	-0.23	0.27	0.47	-0.12	0.31	-0.49	0.14	0.13	-0.35	-0.56	0.28	-0.37
Total Stockholder Equity	0.66	-0.22	0.12	-0.75	-0.15		-0.32	1.0	0.47	0.55	-0.23	-0.33	-0.64	-0.81	-0.05	0.35	-0.13	-0.47	0.13	0.58	0.57	-0.69	-0.4	-0.3	0.66	-0.31
Other Liab	-0.91	0.97	-0.7	0.68	-0.27	-0.32		-0.33	-0.52	-0.27	0.94	0.03	0.65	0.45	0.65	-0.1	0.08	0.75	-0.48	0.14	-0.39	0.51	0.87	0.82	-0.89	0.99
Net Tangible Assets	0.66	-0.22	0.11	-0.75	-0.15	1.0	-0.33		0.47	0.58	-0.23	-0.34	-0.65	-0.81	-0.13	0.35	-0.11	-0.51	0.14	0.59	0.58	-0.7	-0.39	-0.28	0.67	-0.31
Net Debt	0.6	-0.48	0.57	-0.78	-0.03	0.47	-0.52	0.47		0.35	-0.61	-0.64	-0.9	-0.82	-0.35	0.38	-0.68	-0.23	0.61	0.59	0.51	-0.89	-0.43	-0.27	0.64	-0.49
Retained Earnings	0.44	-0.25	-0.12	-0.28	-0.09	0.55	-0.27	0.58	0.35		-0.36	-0.42	-0.32	-0.36	-0.21	0.66	-0.29	-0.52	0.04	0.16	0.69	-0.33	0.03	0.05	0.54	-0.29
Accounts Payable	-0.83	0.94	-0.65	0.59	-0.15	-0.23	0.94	-0.23	-0.61	-0.36		0.18	0.64	0.43	0.53	-0.17	0.37	0.61	-0.51	0.11	-0.39	0.51	0.72	0.64	-0.82	0.94
Cash	-0.13	-0.1	0.2	0.26	0.62	-0.33	0.03	-0.34	-0.64	-0.42	0.18		0.45	0.51	0.02	-0.36	0.7	0.04	0.02	-0.63	-0.47	0.54	-0.07	-0.28	-0.16	-0.07
Non Current Assets Total	-0.75	0.6	-0.57	0.92	0.02	-0.64	0.65	-0.65	-0.9	-0.32	0.64	0.45		0.95	0.46	-0.13	0.48	0.42	-0.73	-0.63	-0.36	0.98	0.61	0.45	-0.76	0.62
Non Currrent Assets Other	-0.66	0.37	-0.38	0.89	0.17	-0.81	0.45	-0.81	-0.82	-0.36	0.43	0.51	0.95		0.27	-0.16	0.46	0.34	-0.57	-0.79	-0.39	0.98	0.48	0.31	-0.67	0.42
Other Assets	-0.5	0.65	-0.47	0.4	-0.23	-0.05	0.65	-0.13	-0.35	-0.21	0.53	0.02	0.46	0.27		0.12	-0.18	0.64	-0.49	0.04	-0.1	0.38	0.47	0.4	-0.55	0.63
Long Term Debt	0.29	-0.08	0.11	-0.26	0.27	0.35	-0.1	0.35	0.38	0.66	-0.17	-0.36	-0.13	-0.16	0.12		-0.21	-0.2	-0.17	0.01	0.91	-0.13	0.01	-0.08	0.38	-0.12
Cash And Short Term Investments	-0.1	0.08	-0.06	0.2	0.47	-0.13	0.08	-0.11	-0.68	-0.29	0.37	0.7	0.48	0.46	-0.18	-0.21		-0.23	-0.32	-0.5	-0.18	0.51	-0.11	-0.28	-0.12	0.06
Net Receivables	-0.73	0.67	-0.25	0.48	-0.12	-0.47	0.75	-0.51	-0.23	-0.52	0.61	0.04	0.42	0.34	0.64	-0.2	-0.23		-0.19	0.07	-0.49	0.35	0.56	0.62	-0.74	0.71
Good Will	0.42	-0.57	0.6	-0.58	0.31	0.13	-0.48	0.14	0.61	0.04	-0.51	0.02	-0.73	-0.57	-0.49	-0.17	-0.32	-0.19		0.33	-0.13	-0.68	-0.39	-0.36	0.45	-0.52
Short Term Investments	0.08	0.23	-0.07	-0.47	-0.49	0.58	0.14	0.59	0.59	0.16	0.11	-0.63	-0.63	-0.79	0.04	0.01	-0.5	0.07	0.33		0.1	-0.76	0.06	0.23	0.1	0.2
Long Term Debt Total	0.58	-0.3	0.21	-0.51	0.14	0.57	-0.39	0.58	0.51	0.69	-0.39	-0.47	-0.36	-0.39	-0.1	0.91	-0.18	-0.49	-0.13	0.1		-0.35	-0.31	-0.32	0.64	-0.37
Non Current Liabilities Total	-0.66	0.44	-0.45	0.88	0.13	-0.69	0.51	-0.7	-0.89	-0.33	0.51	0.54	0.98	0.98	0.38	-0.13	0.51	0.35	-0.68	-0.76	-0.35		0.5	0.32	-0.67	0.47
Capital Surpluse	-0.87	0.82	-0.72	0.77	-0.35	-0.4	0.87	-0.39	-0.43	0.03	0.72	-0.07	0.61	0.48	0.47	0.01	-0.11	0.56	-0.39	0.06	-0.31	0.5		0.92	-0.8	0.85
Other Current Assets	-0.79	0.79	-0.71	0.67	-0.56	-0.3	0.82	-0.28	-0.27	0.05	0.64	-0.28	0.45	0.31	0.4	-0.08	-0.28	0.62	-0.36	0.23	-0.32	0.32	0.92		-0.73	0.82
Other Stockholder Equity	0.99	-0.85	0.63	-0.86	0.28	0.66	-0.89	0.67	0.64	0.54	-0.82	-0.16	-0.76	-0.67	-0.55	0.38	-0.12	-0.74	0.45	0.1	0.64	-0.67	-0.8	-0.73		-0.89
Total Liab	-0.91	0.99	-0.74	0.67	-0.37	-0.31	0.99	-0.31	-0.49	-0.29	0.94	-0.07	0.62	0.42	0.63	-0.12	0.06	0.71	-0.52	0.2	-0.37	0.47	0.85	0.82	-0.89

Click cells to compare fundamentals

Axa Equitable Account Relationship Matchups

Axa Equitable fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	493.6M	450.4M	417.4M	379.9M	351.6M	391.5M
Total Assets	249.9B	282.3B	292.3B	252.7B	266.8B	271.6B
Short Long Term Debt Total	4.1B	4.1B	5.1B	5.2B	4.7B	4.0B
Other Current Liab	(2.1B)	(2.8B)	(2.8B)	(714M)	2.2B	2.3B
Total Current Liabilities	2.1B	2.8B	2.8B	3.0B	5.1B	2.8B
Total Stockholder Equity	13.5B	15.6B	11.5B	1.4B	2.6B	2.5B
Other Liab	215.6B	251.1B	272.3B	232.4B	267.3B	237.9B
Net Tangible Assets	7.7B	11.0B	5.2B	(3.4B)	(3.0B)	(2.9B)
Net Debt	(294M)	(2.1B)	(66M)	950M	(4.5B)	(4.2B)
Retained Earnings	11.8B	10.7B	8.9B	9.8B	10.2B	8.8B
Accounts Payable	2.1B	2.8B	2.7B	2.2B	2.7B	2.5B
Cash	4.4B	6.2B	5.2B	4.3B	9.1B	6.2B
Non Current Assets Total	79.5B	93.8B	88.2B	74.2B	243.3B	255.5B
Non Currrent Assets Other	(79.5B)	(93.8B)	(88.2B)	(1.2B)	227.7B	239.0B
Other Assets	159.4B	93.5B	181.6B	81.1B	147.3B	130.0B
Long Term Debt	6.4B	4.1B	5.0B	4.5B	5.4B	4.6B
Cash And Short Term Investments	4.4B	88.2B	5.2B	4.3B	75.3B	79.0B
Net Receivables	6.6B	6.8B	17.3B	11.6B	12.2B	10.2B
Good Will	4.6B	4.6B	4.6B	5.1B	4.6B	3.8B
Short Term Investments	66.3B	82.0B	79.9B	64.9B	1.5B	1.4B
Long Term Debt Total	6.4B	4.1B	3.9B	3.3B	3.0B	4.4B
Liabilities And Stockholders Equity	249.9B	282.3B	292.3B	252.7B	266.8B	271.6B
Non Current Liabilities Total	4.7B	4.9B	5.0B	3.3B	256.5B	269.3B
Capital Surpluse	1.9B	2.0B	1.9B	2.3B	2.6B	1.8B
Other Current Assets	14.2B	21.3B	27.6B	29.7B	23.5B	18.8B
Other Stockholder Equity	88M	(260M)	(931M)	(998M)	(1.4B)	(1.3B)
Total Liab	234.4B	265.0B	278.7B	249.1B	261.6B	257.4B
Deferred Long Term Liab	5.9B	749M	5.5B	8.2B	7.4B	4.5B
Long Term Investments	74.7B	109.1B	105.1B	93.1B	75.2B	84.7B
Short Long Term Debt	2.9B	546M	92M	759M	254M	241.3M
Total Current Assets	11.0B	95.0B	22.5B	97.4B	23.5B	42.2B
Accumulated Other Comprehensive Income	840M	3.9B	2.0B	(9.0B)	(7.8B)	(7.4B)
Short Term Debt	4.1B	4.1B	92M	759M	254M	241.3M
Intangible Assets	4.8B	4.7B	4.7B	5.5B	5.4B	4.5B
Cash And Equivalents	4.4B	6.2B	5.2B	4.3B	3.9B	4.0B
Net Invested Capital	16.9B	18.7B	15.1B	5.3B	6.7B	11.6B
Warrants	365M	143M	468M	455M	523.3M	356.0M
Noncontrolling Interest In Consolidated Entity	1.6B	1.6B	1.6B	1.7B	2.0B	1.8B
Retained Earnings Total Equity	11.8B	10.7B	8.9B	9.9B	8.9B	8.9B

Currently Active Assets on Macroaxis

V	Visa Class A
BAC	Bank of America
GM	General Motors
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Axa Equitable Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Axa Equitable's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Axa Equitable Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Axa Equitable Holdings Stock:

How To Invest In Axa

Details

Is Axa Stock a good investment?

Details

What is Axa Equitable's Net Worth?

Details

Largest Diversified Financial Services Companies

View

Largest Insurance - Diversified Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Axa Equitable Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Axa Stock analysis

When running Axa Equitable's price analysis, check to measure Axa Equitable's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axa Equitable is operating at the current time. Most of Axa Equitable's value examination focuses on studying past and present price action to predict the probability of Axa Equitable's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axa Equitable's price. Additionally, you may evaluate how the addition of Axa Equitable to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Axa Equitable's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axa Equitable. If investors know Axa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axa Equitable listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

0.9

Earnings Share

3.33

Revenue Per Share

30.362

Quarterly Revenue Growth

(0.05)

The market value of Axa Equitable Holdings is measured differently than its book value, which is the value of Axa that is recorded on the company's balance sheet. Investors also form their own opinion of Axa Equitable's value that differs from its market value or its book value, called intrinsic value, which is Axa Equitable's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axa Equitable's market value can be influenced by many factors that don't directly affect Axa Equitable's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axa Equitable's value and its price as these two are different measures arrived at by different means. Investors typically determine if Axa Equitable is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axa Equitable's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axa Deferred Long Term Liab vs Cash And Equivalents Analysis

Deferred Long Term Liab vs Cash And Equivalents

Deferred Long Term Liab vs Cash And Equivalents Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Cash And Equivalents

Axa Equitable fundamental ratios Correlations

Axa Equitable Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axa Equitable fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Axa Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Liab	+ 0.99	Total Assets
Total Liab	+ 0.99	Other Liab
Non Current Liabilities Total	+ 0.98	Non Current Assets Total
Non Current Liabilities Total	+ 0.98	Non Currrent Assets Other

Total Liab	- 0.91	Common Stock Shares Outstanding
Other Liab	- 0.91	Common Stock Shares Outstanding
Non Current Assets Total	- 0.9	Net Debt
Total Liab	- 0.89	Other Stockholder Equity
Non Current Liabilities Total	- 0.89	Net Debt
Other Stockholder Equity	- 0.89	Other Liab